A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
OCRA Discusses New Findings on Gaps in Genetic Testing with Patient Power
A new article from Patient Power highlights findings from a paper authored by Ovarian Cancer Research Alliance (OCRA) and Komodo Health, that reveals significant gaps in genetic testing for ovarian … Continued
Advocate’s Corner: April 2025
Spring is here—and so is appropriations season in Washington, DC. This month has brought key developments in both the FY26 federal budget process and state-level policy action that could impact gynecologic cancer … Continued
OCRA’s Early Career Investigator Grant Recipients
Ovarian Cancer Research Alliance is proud to support five outstanding scientists through our Early Career Investigator Grants, part of the $6 million in new research OCRA is funding in 2025. These … Continued